ABIRATERONA PHARMAZAC 250mg tablets medication leaflet

L02BX03 abiraterone • Antineoplastic and immunomodulating agents | Hormone antagonists and related agents | Other hormone antagonists and related agents

Abiraterone is a medication used in the treatment of metastatic castration-resistant prostate cancer. It works by inhibiting an enzyme called CYP17, which is essential for the production of androgens, hormones that stimulate the growth of prostate cancer cells.

Abiraterone is administered alongside prednisone or prednisolone to reduce side effects caused by decreased cortisol levels. Treatment with abiraterone can slow disease progression and improve patients' quality of life.

Common side effects include high blood pressure, hypokalemia (low potassium levels in the blood), and fluid retention. It is important for patients to undergo regular monitoring of liver function and blood pressure during treatment.

Abiraterone is contraindicated in pregnant or breastfeeding women and is not recommended for use in patients with severe liver impairment.

General data about ABIRATERONA PHARMAZAC 250mg

Substance: abiraterone

Date of last drug list: 01-06-2025

Commercial code: W67872001

Concentration: 250mg

Pharmaceutical form: tablets

Quantity: 120

Product type: generic

Price: 2251.78 RON

Prescription restrictions: P-RF - Medicines prescription that is retained in the pharmacy (not renewable).

Marketing authorisation

Manufacturer: SYNTHON HISPANIA, S.L. - SPANIA

Holder: PHARMAZAC S.A. - GRECIA

Number: 13898/2021/

Shelf life: 2 years

Pharmaceutical forms available for abiraterone

Concentrations available for abiraterone

1000mg, 250mg, 500mg

Other substances similar to abiraterone

Combinations with other substances

Compensation lists for ABIRATERONA PHARMAZAC 250mg PHARMAZAC

NHP 3 (C2) - NHP oncology

Price

Copayment

Patient

2251.78 RON

2251.78 RON

0.00 RON